<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603590</url>
  </required_header>
  <id_info>
    <org_study_id>301/148</org_study_id>
    <secondary_id>CCT-NAPN 15388</secondary_id>
    <nct_id>NCT00603590</nct_id>
  </id_info>
  <brief_title>Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease</brief_title>
  <acronym>Polypill</acronym>
  <official_title>Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular is a major cause of mortality in Iran, accounting for 45.7% of deaths. In
      Golestan (North Eastern Iran) preliminary findings from follow-up of the Golestan Cohort are
      consistent with national figures: with 45% (at least 22 of 48 deaths) of all deaths
      attributed to cardiovascular events. Cardiovascular diseases will become an increasing
      problem as the Iranian population ages.

      In 2003 Law and Wald proposed prevention of cardiovascular disease using fixed-dose
      combination therapy combining antihypertensive, lipid lowering and antiplatelet drugs in a
      single preparation. They proposed that this treatment should be offered to all persons at
      high risk of cardiovascular disease whether or not they have elevated blood pressure or
      elevated serum lipid concentrations.

      This pilot study aims to investigate the safety and efficacy of fixed-dose combination
      therapy with two antihypertensive drugs, aspirin and atorvastatin in a population who would
      not currently be considered eligible for antihypertensive treatment or for lipid lowering
      treatment.

      Methods:

      This is a double-blind randomized controlled trial. The intervention group will be assigned
      to take a tablet consisting of a single daily tablet comprising Aspirin 81mg,
      Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg. The control group will be
      assigned to an identical placebo.

      The population studied includes men aged 50 to 80 (inclusive) and women aged 55 to 80
      (inclusive) who are currently not eligible for or taking antihypertensive or lipid lowering
      therapy. Persons who are found at baseline to have blood pressure &gt;160/100 mm Hg, total
      cholesterol &gt;240mg/dL, existing cardiovascular disease or to be taking antihypertensive ore
      lipid lowering therapy are excluded.

      It is intended to randomize and follow up 500 subjects for 12 months. The primary outcome for
      the purpose of sample size calculation is change in systolic blood pressure. Additional
      outcomes include change in diastolic blood pressure, change in LDL cholesterol and occurrence
      of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill</intervention_name>
    <description>Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily</description>
    <arm_group_label>Polypill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drug</intervention_name>
    <description>Inactive tablet Once a day Identical in appearance to intervention drug</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        All men over 50 to 80 and all women 55 to 80 who are resident in Kalaleh, Golestan, for at
        least one year.

        Exclusion criteria

          -  Existing cardiovascular disease (stroke, transient ischaemic attack, myocardial
             infarction or angina)

          -  Already taking antihypertensive drugs, aspirin or statins

          -  Already have clinical indications for treatment with antihypertensive drugs, aspirin
             or statins.

               -  Blood pressure &gt;160/100 mm Hg

               -  Total Cholesterol &gt; 240 mg/dL (or LDL &gt;190 mg/dL)

          -  Probable diabetes: HbA1c &gt;6.0

        Contraindication to a component of the Polypill

        Contraindications to aspirin

          -  Previous history of allergy to aspirin

          -  History of peptic ulcer bleeding in whole life or endoscopic evidence of peptic ulcer
             within the past 3 months

        Contraindications to statins

          -  Liver failure Contraindications to further blood pressure lowering

          -  Systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤70 mm Hg

          -  Symptomatic postural hypotension

          -  Difference between mean seated BP and standing BP greater than 20 mm Hg

        Contraindications to thiazide

          -  Uric acid &gt;8 for men and uric acid &gt;6 for women / gout (~10%)

          -  Creatinine &gt;1.2 mg/dl

        Other predominant medical problem that may limit compliance with study treatment including:

          -  History of alcohol abuse: more than 60cc for women and more than 80cc for men

          -  History of drug abuse: IV drug abuser or eating or smoking more than 4 times a week

          -  Limiting psychiatric illness (eg: mania, schizophrenia, severe depression, psychosis
             or dementia)

          -  Limiting physical disability sufficient to prevent subject from walking

          -  Other life-threatening condition such as cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatemeh Malekzadeh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mansoor Rastegarpanah, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kar K Cheng, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom P Marshall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akram Pourshams, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kalaleh Heart Study Center</name>
      <address>
        <city>Kalaleh</city>
        <state>Golestan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by &quot;heart polypill&quot;? Arch Iran Med. 2008 May;11(3):306-13. doi: 08113/AIM.0012.</citation>
    <PMID>18426322</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <results_first_submitted>April 13, 2009</results_first_submitted>
  <results_first_submitted_qc>May 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2009</results_first_posted>
  <last_update_submitted>September 22, 2009</last_update_submitted>
  <last_update_submitted_qc>September 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Reza Malekzadeh</name_title>
    <organization>Tehran University of Medical Sciences</organization>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>primary prevention</keyword>
  <keyword>Polypill</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>ADR</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Adherence</keyword>
  <keyword>Compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between July 2006 and January 2007, 1,733 subjects attended the Kalaleh heart clinic. Of those assessed 872 were included in the run-in phase of the study. Of these 475 were randomized.</recruitment_details>
      <pre_assignment_details>872 subjects entered the run in phase, 258 were excluded. Most exclusions were due to laboratory test results.
614 completed the run-in phase of the study, 65 were excluded. Most were excluded because they did not attend the clinic.
Of 549 subjects remaining, 74 were not randomized.
475 subjects who were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Polypill</title>
          <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Identical placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>One Month</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Four Months</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eight Months</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not attend study clinic</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused blood test</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient discontinued study drug</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cardiovascular event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Polypill</title>
          <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Identical placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="241"/>
            <count group_id="B2" value="234"/>
            <count group_id="B3" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="6.5"/>
                    <measurement group_id="B2" value="59.1" spread="7.3"/>
                    <measurement group_id="B3" value="59.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Mean of two seated blood presures</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" spread="10.4"/>
                    <measurement group_id="B2" value="81.2" spread="9.7"/>
                    <measurement group_id="B3" value="79.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL cholesterol</title>
          <description>Serum LDL cholesterol levels</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.7" spread="25.8"/>
                    <measurement group_id="B2" value="116.6" spread="24.8"/>
                    <measurement group_id="B3" value="116.6" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Mean of two seated systolic blood pressures</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.8" spread="17.3"/>
                    <measurement group_id="B2" value="130.3" spread="17.4"/>
                    <measurement group_id="B3" value="127.5" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure. Mean of two seated measurements.</description>
        <time_frame>One year</time_frame>
        <population>Intention to treat Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Polypill</title>
            <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Identical placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure. Mean of two seated measurements.</description>
          <population>Intention to treat Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.7" spread="16.8"/>
                    <measurement group_id="O2" value="129.7" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Mean of two seated diastolic blood pressures</description>
        <time_frame>One year</time_frame>
        <population>Analysis by intention to treat. Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Polypill</title>
            <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Identical placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Mean of two seated diastolic blood pressures</description>
          <population>Analysis by intention to treat. Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="10.6"/>
                    <measurement group_id="O2" value="81.3" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol</title>
        <description>Serum LDL cholesterol</description>
        <time_frame>One year</time_frame>
        <population>Intention to treat Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Polypill</title>
            <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Identical placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <description>Serum LDL cholesterol</description>
          <population>Intention to treat Results shown here are based on 12 month observation. Analysis for final paper will be last observation carried forward</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" spread="26.7"/>
                    <measurement group_id="O2" value="112.0" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Polypill</title>
          <description>Polypill (Atorvastatin 20 mg, Asprin 81 mg, Enalapril 2.5 mg, Hydrochlorothiazide 12.5 mg)</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Identical placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Incomplete follow up Because of differences in systolic blood pressure at baseline, final analysis will take account of baseline differences</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mansoor Rastegarpanah</name_or_title>
      <organization>Tehran University of Medical Sciences</organization>
      <phone>+989121255960</phone>
      <email>rastegar@sina.tums.ac.ir</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

